lactic acid has been researched along with bosentan anhydrous in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alving, K; Oldner, A; Rudehill, A; Sollevi, A; Wanecek, M; Weitzberg, E | 1 |
| Gu, T; Mao, N; Shi, E; Xie, P; Zhang, Y | 1 |
| Basalious, EB; ELGazayerly, ON; Hanna, LA | 1 |
4 other study(ies) available for lactic acid and bosentan anhydrous
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan.
Topics: Acid-Base Imbalance; Animals; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; Endothelin-1; Female; Hemoglobins; Hypertension, Pulmonary; Lactic Acid; Male; Oxygen Consumption; Shock, Septic; Sulfonamides; Swine; Treatment Outcome; Tumor Necrosis Factor-alpha | 1997 |
Inhibition of intimal hyperplasia of the vein graft with degradable poly lactic-co-glycolic acid vascular external sheaths carrying slow-release bosentan.
Topics: Animals; Blood Vessel Prosthesis; Bosentan; Delayed-Action Preparations; Endothelin Receptor Antagonists; Hyperplasia; Jugular Veins; Lactic Acid; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits; Sulfonamides; Tunica Intima; Vascular Grafting | 2015 |
Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption.
Topics: Administration, Inhalation; Aerosols; Animals; Antihypertensive Agents; Biological Availability; Bosentan; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Endothelin Receptor Antagonists; Half-Life; Lactic Acid; Lung; Male; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pulmonary Circulation; Rats, Wistar; Respiratory Tract Absorption; Sulfonamides; Vasodilation | 2016 |